HIV Citation List: November 27 - December 10, 2008
Anti*HIV
1. Kuguacins F-S, cucurbitane triterpenoids from Momordica charantia.
Chen JC, Liu WQ, Lu L, Qiu MH, Zheng YT, Yang LM, Zhang XM, Zhou L, Li ZR.
Phytochemistry. 2008 Nov 28. [Epub ahead of print]
PMID: 19041990 [PubMed - as supplied by publisher]
2. A palladium-mediated cascade cyclisation approach to the CDE cores of rubriflordilactone A and lancifodilactone G.
Cordonnier MC, Jennifer Kan SB, Anderson EA.
Chem Commun (Camb). 2008 Nov 30;(44):5818-20. Epub 2008 Oct 2.
PMID: 19009092 [PubMed - in process]
3. Novel synthesis and anti-HIV activity of 4'-branched exomethylene carbocyclic nucleosides using a ring-closing metathesis of triene.
Li H, Yoo JC, Hong JH.
Nucleosides Nucleotides Nucleic Acids. 2008 Dec;27(12):1238-49.
PMID: 19003569 [PubMed - in process]
4. Design and synthesis of novel 2',3'-dideoxy-4'-selenonucleosides as potential antiviral agents.
Jeong LS, Choi YN, Tosh DK, Choi WJ, Kim HO, Choi J.
Bioorg Med Chem. 2008 Dec 1;16(23):9891-7. Epub 2008 Oct 17.
PMID: 18977147 [PubMed - in process]
5. Novel targets for HIV therapy.
Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T.
Antiviral Res. 2008 Dec;80(3):251-65. Epub 2008 Sep 30.
PMID: 18789977 [PubMed - in process]
6. Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages.
Wang X, Douglas SD, Song L, Wang YJ, Ho WZ.
J Neuroimmune Pharmacol. 2008 Dec;3(4):257-64. Epub 2008 Jul 25.
PMID: 18654860 [PubMed - in process]
7. Oleanolic acid and related derivatives as medicinally important compounds.
Sultana N, Ata A.
J Enzyme Inhib Med Chem. 2008 Dec;23(6):739-56.
PMID: 18618318 [PubMed - in process]
8. Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones.
Roy K, Mandal AS.
J Enzyme Inhib Med Chem. 2008 Dec;23(6):980-95.
PMID: 18608761 [PubMed - in process]
9. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E.
Eur J Med Chem. 2008 Dec;43(12):2800-6. Epub 2007 Dec 27.
PMID: 18242784 [PubMed - in process]
10. Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.
Berchanski A, Lapidot A.
J Mol Model. 2008 Dec 5. [Epub ahead of print]
PMID: 19057930 [PubMed - as supplied by publisher]
(Drug or Compound or Therapeutic) and (HIV or AIDS or Human Immunodeficiency Virus)
11. The Relative Activity of 'Function Sparing' HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property?
Muniz-Medina V, Jones S, Maglich J, Galardi C, Hollingsworth R, Kazmierski W, Ferris R, Edelstein M, Chiswell K, Kenakin T.
Mol Pharmacol. 2008 Dec 8. [Epub ahead of print]
PMID: 19064629 [PubMed - as supplied by publisher]
12. Specific interactions between the viral co-receptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.
Thakkar N, Pirrone V, Passic S, Zhu W, Kholodovych V, Welsh W, Rando RF, Labib ME, Wigdahl B, Krebs FC.
Antimicrob Agents Chemother. 2008 Dec 1. [Epub ahead of print]
PMID: 19047650 [PubMed - as supplied by publisher]
13. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP.
J Med Virol. 2008 Dec;80(12):2053-63.
PMID: 19040279 [PubMed - in process]
(HIV or Aids or "human immunodeficiency virus") and (inhibit*)
14. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.
Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA.
J Virol. 2008 Dec;82(24):12069-81. Epub 2008 Oct 8.
PMID: 18842738 [PubMed - in process]
15. Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor: EQUIPOTENT TO C34 AND T-20 IN VITRO WITH SUSTAINED ACTIVITY IN SCID-HU THY/LIV MICE.
Stoddart CA, Nault G, Galkina SA, Thibaudeau K, Bakis P, Bousquet-Gagnon N, Robitaille M, Bellomo M, Paradis V, Liscourt P, Lobach A, Rivard ME, Ptak RG, Mankowski MK, Bridon D, Quraishi O.
J Biol Chem. 2008 Dec 5;283(49):34045-52. Epub 2008 Sep 22.
PMID: 18809675 [PubMed - in process]
(HIV or Aids or "human immunodeficiency virus") and (protease or proteinase)
16. Target-selective photo-degradation of HIV-1 protease by a fullerene-sugar hybrid.
Tanimoto S, Sakai S, Matsumura S, Takahashi D, Toshima K.
Chem Commun (Camb). 2008 Nov 30;(44):5767-9. Epub 2008 Oct 2.
PMID: 19009075 [PubMed - in process]
17. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein.
Kar AK, Diaz-Griffero F, Li Y, Li X, Sodroski J.
J Virol. 2008 Dec;82(23):11669-81. Epub 2008 Sep 17.
PMID: 18799572 [PubMed - in process]
18. Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus.
Wong JH, Wang HX, Ng TB.
Appl Microbiol Biotechnol. 2008 Dec;81(4):669-74. Epub 2008 Aug 27.
PMID: 18751697 [PubMed - in process]
Journal Check
19. Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase.
Kodama E, Orita M, Masuda N, Yamomoto O, Fujii M, Ohgami T, Kageyama S, Ohta M, Hatta T, Inoue H, Suzuki H, Sudo K, Shimizu Y, Matsuoka M.
Antivir Chem Chemother. 2008;19(3):133-41.
PMID: 19024630 [PubMed - in process]